A method for the treatment of a neurodegenerative, psychiatric or neurological disease associated with a cholinergic deficit comprising administering GLN-1062 or a pharmaceutically acceptable salt thereof by nasal administration to a patient in need thereof.

##STR00001##

A method for the treatment of a neurodegenerative, psychiatric or neurological disease associated with a cholinergic deficit comprising administering GLN-1062 or a pharmaceutically acceptable salt thereof by nasal administration to a patient in need thereof.

##STR00001##

The disclosure includes compounds of Formula (I)

##STR00001## wherein R.sub.0, R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, and L are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.

Specific polycyclic compounds of the general formula (I) and a process for its preparation, an electronic device comprising at least one of these compounds, an emitting layer, preferably present in an electronic device, comprising at least one compound of general formula (I) and the use of compounds according to general formula (I) in an electronic device as a host material, a charge transporting material, charge and/or exciton blocking material, preferably as a host material or an electron transporting material. ##STR00001##

Specific polycyclic compounds of the general formula (I) and a process for its preparation, an electronic device comprising at least one of these compounds, an emitting layer, preferably present in an electronic device, comprising at least one compound of general formula (I) and the use of compounds according to general formula (I) in an electronic device as a host material, a charge transporting material, charge and/or exciton blocking material, preferably as a host material or an electron transporting material. ##STR00001##

The present invention provides an intermediate compound for easily producing a compound having an azaperylene skeleton. Another object of the present invention is to provide a method for easily producing a compound having an azaperylene skeleton.

The compound of the present invention is a compound represented by Formula (I), or a compound represented by Formula (II).

##STR00001##

An organic electroluminescence device includes an anode, a cathode, a first emitting layer, and a second emitting layer provided between the first emitting layer and the cathode, in which the first emitting layer includes, as a first host material, a first compound that includes at least one group represented by a formula (11) below, the first compound being represented by a formula (1) below, the second emitting layer includes a second compound represented by a formula (2) below as a second host material, and the first emitting layer is in direct contact with the second emitting layer. L.sub.101 is a single bond or a substituted or unsubstituted arylene group having 6 to 50 ring carbon atoms. Ar.sub.101 is a substituted or unsubstituted aryl group having 6 to 50 ring carbon atoms. mx is 0, 1, 2, 3, 4, or 5.

##STR00001##

An organic electroluminescence device includes an anode, a cathode, a first emitting layer, and a second emitting layer provided between the first emitting layer and the cathode, in which the first emitting layer includes, as a first host material, a first compound that includes at least one group represented by a formula (11) below, the first compound being represented by a formula (1) below, the second emitting layer includes a second compound represented by a formula (2) below as a second host material, and the first emitting layer is in direct contact with the second emitting layer. L.sub.101 is a single bond or a substituted or unsubstituted arylene group having 6 to 50 ring carbon atoms. Ar.sub.101 is a substituted or unsubstituted aryl group having 6 to 50 ring carbon atoms. mx is 0, 1, 2, 3, 4, or 5.

##STR00001##

The invention relates to inhibitors of PI5P4K inhibitors useful in the treatment of cancers, neurodegenerative diseases, inflammatory disorders, and metabolic diseases, having the Formula:

##STR00001##

where A, B, R.sub.1, X.sub.1, X.sub.2, and W are described herein.

The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent device having a low driving voltage and/or a high luminous efficiency and/or a long lifespan can be provided, by comprising an organic electroluminescent compound according to the present disclosure.